NTRA
NASDAQ · Biotechnology
Natera Inc
$310.67
-53.09 (-14.59%)
NTRA News4 articles
Tempus AI Dips After Hours Despite Q2 Beat; Focus Shifts to H2 Profitability
Tempus AI slipped 2.6% in after-hours trade despite a slight Q2 revenue beat and raised full-year guidance, as markets scrutinize the company's ability to ramp margins in the second half.
Tempus AI Shares Tumble 19% as Personalis Deal Terms Come Under Scrutiny
Tempus AI shares dropped nearly 19% over the past week, closing at $42.69 and falling below both reference points in its proposed acquisition of Personalis.
Tempus AI Shares Near Deal Termination Threshold After 7.8% Drop
Tempus AI shares dropped 7.8% to $48.39, nearing the $46 threshold that could trigger a termination right for Personalis, wiping $730 million from market cap.
Natera Shares Slide Despite FDA Approval for Bladder Cancer Test
Natera shares dropped 5.36% Friday, even after the FDA approved its Signatera CDx test for use with Genentech's Tecentriq in muscle-invasive bladder cancer. The stock closed at $186.36.